Mums whose babies developed life‑threatening sepsis and meningitis from group B streptococcus are urging pregnant women to join a new vaccine study.
The BEATRIX study, supported by the NIHR and sponsored by Pfizer, is the first large‑scale phase 3 vaccine trial for GBS. Researchers from the NHS and UK universities, alongside international partners, aim to prevent avoidable infant deaths and stillbirths.
GBS is the leading cause of life‑threatening infection in newborns, causing sepsis, pneumonia and meningitis. Around 1 in every 1,000 babies in the UK and Ireland develops GBS infection in the first three months of life. Each year, GBS kills 50 babies and leaves around 70 with long‑term disabilities.
Professor Paul Heath, Chief Investigator of the BEATRIX study, said: “Group B Streptococcus can cause serious illness in newborn babies, yet there is currently no licensed vaccine available to help prevent these infections.” He added: “The BEATRIX study is evaluating an investigational maternal vaccine and aims to expand our understanding of maternal immunisation against GBS.”
Professor Lucy Chappell, Chief Executive Officer of the NIHR, explained: “Stories like Leo’s highlight why research matters. Behind every study are families with a shared determination to find better ways to prevent serious illness and improve outcomes for others.” She continued: “Every woman who takes part brings us closer to the evidence we need to protect babies and mothers.”
Health Innovation Minister James Frith said: “No parent should have to face the fear that Laura and Matt did. Their story is a powerful reminder of why these studies matter so much.” He added: “By working in partnership across the life sciences sector, we can accelerate innovation and deliver lasting benefits for patients and the public for decades to come.”
